CE Information and Faculty Disclosures

• TARGET AUDIENCE
  This program is intended for medical and gynecologic oncologists, hematology-oncology fellows and other healthcare providers involved in the treatment of gynecologic cancers.
  
  LEARNING OBJECTIVES

  • Assess available clinical trial data with and approved indications for FDA-endorsed PARP inhibitors for newly diagnosed and recurrent ovarian cancer (OC) to optimally incorporate these agents into patient care.
  • Appreciate the biological rationale for and published clinical research data with the use of PARP inhibitors in combination with other systemic therapies, and consider the implications of these findings for current and future OC management.
  • Recognize the rationale for targeting folate receptor alpha in OC, and determine optimal methods to test for and the current role of novel approaches to therapeutically exploit this newly relevant biomarker.
  • Consider available and emerging clinical research findings with anti-PD-1/PD-L1 antibodies in combination with chemotherapy as first-line treatment for advanced or recurrent endometrial cancer (EC), and consider the current and future role of this novel strategy in the care of patients with microsatellite instability (MSI)-high/mismatch repair-deficient (dMMR) and microsatellite-stable/mismatch repair-proficient disease.
  • Review the benefits observed with anti-PD-1/PD-L1 antibodies as monotherapy for MSI-high/dMMR EC, and integrate these agents into the care of appropriate patients with relapsed/refractory disease.
  • Recognize available data with anti-PD-1/PD-L1 antibodies in combination with agents targeting the VEGF pathway, and select patients with metastatic EC for treatment with this novel approach.
  • Interrogate published efficacy and safety findings with anti-PD-1/PD-L1 antibodies as monotherapy or in combination with chemotherapy with and without anti-VEGF therapy for patients with metastatic cervical cancer (CC), and consider the current and future role of immune checkpoint inhibition in the treatment of this disease.
  • Reflect on investigational agents and strategies currently in testing for OC, EC and CC, and refer eligible patients for clinical trial participation.

  ACCREDITATION STATEMENT
  Research To Practice is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
  
  CREDIT DESIGNATION STATEMENT
  CME credit is no longer available for this issue
  
  AMERICAN BOARD OF INTERNAL MEDICINE (ABIM) — MAINTENANCE OF CERTIFICATION (MOC)
  CME credit is no longer available for this issue
  
  PRIVACY POLICY
  Personal information and data sharing: Research To Practice aggregates deidentified user data for program-use analysis, program development, activity planning and site improvement. We may provide aggregate and deidentified data to third parties, including commercial supporters. We do not share or sell personally identifiable information to any unaffiliated third parties or commercial supporters. Please see our privacy policy at ResearchToPractice.com/Privacy-Policy for more information.
  
  HOW TO USE THIS CME ACTIVITY
  Audio Program: This CME activity consists of an audio component.
  CME credit is no longer available for this issue
  
  Video Program: This CME activity consists of a video component.
  CME credit is no longer available for this issue
  
  CONTENT VALIDATION AND DISCLOSURES
  Research To Practice (RTP) is committed to providing its participants with high-quality, unbiased and state-of-the-art education and adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education. Any individuals in a position to control the content of an accredited continuing education activity, including faculty, planners, reviewers and others, are required to disclose all relevant financial relationships with ineligible entities (commercial interests). All relevant conflicts of interest have been mitigated prior to the commencement of this activity. In addition, all activity content is reviewed by RTP scientific staff and an external, independent physician reviewer for fair balance, scientific objectivity of studies referenced and patient care recommendations.
  
  FACULTY — The following faculty reported relevant financial relationships with ineligible entities:
  
  Richard T Penson, MD, MRCP
  Associate Professor of Medicine
  Harvard Medical School
  Associate Physician
  Massachusetts General Hospital
  IRB Chair
  Dana-Farber/Harvard Cancer Center
  Boston, Massachusetts
  
  Advisory Committee: Aadi Bioscience, AstraZeneca Pharmaceuticals LP, GSK, ImmunoGen Inc, Merck, Mersana Therapeutics Inc, Novocure Inc, Roche Laboratories Inc, Sutro Biopharma, VBL Therapeutics; Contracted Research: Array BioPharma Inc, a subsidiary of Pfizer Inc, AstraZeneca Pharmaceuticals LP, Eisai Inc, Genentech, a member of the Roche Group, VBL Therapeutics; Data and Safety Monitoring Board/Committee: AstraZeneca Pharmaceuticals LP, EQRx, Roche Laboratories Inc.
  
  Krishnansu S Tewari, MD
  Professor
  Philip J DiSaia, MD Endowed Chair in Gynecologic Oncology
  Director, Division of Gynecologic Oncology
  Department of Obstetrics and Gynecology
  University of California, Irvine
  Irvine, California
  
  Advisory Committee and Consulting Agreements: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genmab US Inc, GSK, Merck, Regeneron Pharmaceuticals Inc, Seagen Inc; Contracted Research: Genmab US Inc, Karyopharm Therapeutics, Merck, Regeneron Pharmaceuticals Inc, Seagen Inc; Data and Safety Monitoring Board/Committee: Iovance Biotherapeutics; Speakers Bureau: AstraZeneca Pharmaceuticals LP, Eisai Inc, Genmab US Inc, GSK, Merck, Seagen Inc.
  
  MODERATOR — Dr Love is president and CEO of Research To Practice. Research To Practice receives funds in the form of educational grants to develop CME activities from the following companies: AbbVie Inc, Adaptive Biotechnologies Corporation, ADC Therapeutics, Agios Pharmaceuticals Inc, Alexion Pharmaceuticals, Amgen Inc, Array BioPharma Inc, a subsidiary of Pfizer Inc, Astellas, AstraZeneca Pharmaceuticals LP, Aveo Pharmaceuticals, Bayer HealthCare Pharmaceuticals, BeiGene Ltd, BeyondSpring Pharmaceuticals Inc, Blueprint Medicines, Boehringer Ingelheim Pharmaceuticals Inc, Bristol Myers Squibb, Celgene Corporation, Clovis Oncology, Coherus BioSciences, CTI BioPharma Corp, Daiichi Sankyo Inc, Eisai Inc, Elevation Oncology Inc, EMD Serono Inc, Epizyme Inc, Exact Sciences Corporation, Exelixis Inc, Five Prime Therapeutics Inc, Foundation Medicine, G1 Therapeutics Inc, Genentech, a member of the Roche Group, Genmab US Inc, Gilead Sciences Inc, Grail Inc, GSK, Halozyme Inc, Helsinn Healthcare SA, ImmunoGen Inc, Incyte Corporation, Ipsen Biopharmaceuticals Inc, Janssen Biotech Inc, administered by Janssen Scientific Affairs LLC, Jazz Pharmaceuticals Inc, Karyopharm Therapeutics, Kite, A Gilead Company, Kronos Bio Inc, Legend Biotech, Lilly, Loxo Oncology Inc, a wholly owned subsidiary of Eli Lilly & Company, MEI Pharma Inc, Merck, Mersana Therapeutics Inc, Mirati Therapeutics Inc, Natera Inc, Novartis, Novartis Pharmaceuticals Corporation on behalf of Advanced Accelerator Applications, Novocure Inc, Oncopeptides, Pfizer Inc, Pharmacyclics LLC, an AbbVie Company, Puma Biotechnology Inc, Regeneron Pharmaceuticals Inc, R-Pharm US, Sanofi, Seagen Inc, Servier Pharmaceuticals LLC, SpringWorks Therapeutics Inc, Stemline Therapeutics Inc, Sumitomo Dainippon Pharma Oncology Inc, Taiho Oncology Inc, Takeda Pharmaceuticals USA Inc, TerSera Therapeutics LLC, Tesaro, A GSK Company, TG Therapeutics Inc, Turning Point Therapeutics Inc, Verastem Inc, and Zymeworks Inc.
  
  RESEARCH TO PRACTICE CME PLANNING COMMITTEE MEMBERS, STAFF AND REVIEWERS — Planners, scientific staff and independent reviewers for Research To Practice have no relevant conflicts of interest to disclose.
  
  These educational activities contain discussion of published and/or investigational uses of agents that are not indicated by the Food and Drug Administration. Research To Practice does not recommend the use of any agent outside of the labeled indications. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications and warnings. The opinions expressed are those of the presenters and are not to be construed as those of the publisher or grantors.
  
  These activities are supported by educational grants from AstraZeneca Pharmaceuticals LP and Merck.
  
  Release date: November 2023
  Expiration date: November 2024